How should a neonate with a hemodynamically significant patent ductus arteriosus (PDA) causing wide pulse pressure, who is in septic shock and has persistent pulmonary hypertension of the newborn (PPHN), be treated?

Management of Hemodynamically Significant PDA with Wide Pulse Pressure in a Neonate with Septic Shock and PPHN

In this critically complex scenario, prioritize aggressive treatment of septic shock and PPHN first while avoiding PDA closure interventions until hemodynamic stability is achieved, as PDA closure can worsen outcomes when PPHN is active.

Critical Management Priorities

1. Treat Septic Shock First

The presence of septic shock takes precedence. Adequate fluid resuscitation and vasopressor therapy must restore hemodynamic stability before considering any PDA-directed intervention 1. The wide pulse pressure from the PDA is secondary to your primary problem—the septic shock and PPHN.

• Maintain systemic blood pressure at normal levels for age with volume and cardiotonic therapy 2
• Avoid increasing blood pressure to supraphysiological levels solely to drive left-to-right shunt across the PDA—this may transiently improve oxygenation but will not reduce pulmonary vascular resistance and should be avoided 2
• Enteral feeding should not be withheld solely based on vasoactive medication use after adequate hemodynamic resuscitation when vasoactive agents are no longer escalating 1

2. Manage PPHN Aggressively

Inhaled nitric oxide (iNO) is indicated when the oxygenation index exceeds 25 2. This is your primary pulmonary vasodilator therapy.

PPHN Treatment Algorithm:

• Optimize lung recruitment strategies—these improve iNO efficacy and should be performed in patients with PPHN and parenchymal lung disease 2
• Maintain oxygen saturations appropriately but avoid extreme hyperoxia (FiO2 >0.6) which may aggravate lung injury 2
• Avoid acidosis as it induces pulmonary vasoconstriction 2

If iNO-Refractory (30-40% of infants don't respond):

• Intravenous milrinone is reasonable in infants with PPHN and signs of left ventricular dysfunction 2—this is particularly relevant given your hemodynamically significant PDA likely causing LV volume overload
• Sildenafil is reasonable adjunctive therapy for infants refractory to iNO, especially with oxygenation index >25 2
• Consider ECMO support for severe PH or hypoxemia refractory to iNO and optimization of respiratory/cardiac function 2

3. The PDA Paradox in PPHN

Here's the critical nuance: In the setting of active PPHN with suprasystemic pulmonary pressures, the PDA may actually be protective by allowing right-to-left shunting to decompress the right ventricle 3.

Key Considerations:

• The wide pulse pressure indicates left-to-right shunting, suggesting pulmonary pressures have dropped below systemic
• However, with active PPHN, bidirectional or predominantly right-to-left shunting may be occurring
• Echocardiography is essential to determine shunt direction and assess for LV dysfunction 2

4. When to Address the PDA

Do NOT attempt PDA closure while PPHN is active and unstable. The timing is critical:

Wait Until:

• Septic shock is resolved with stable hemodynamics off or on minimal vasopressor support
• PPHN is improving with predominantly left-to-right ductal shunting confirmed by echo
• The infant is no longer requiring escalating respiratory support

Then Consider:

• Close monitoring of the PDA as PPHN resolves—some infants develop cardiac failure secondary to large unrestrictive PDA after recovering from PPHN 3
• If cardiac failure develops with ongoing oxygenation difficulties or myocardial dysfunction despite PPHN resolution, PDA ligation should be considered when other therapeutic options fail 3
• Medical closure (indomethacin/ibuprofen) is less likely to be effective in term infants and may have limited clinical benefit even if ductal diameter decreases 3

Common Pitfalls to Avoid

1. Attempting PDA closure during active PPHN: This can precipitate acute RV failure by eliminating the "pop-off" valve for the right ventricle
2. Aggressive blood pressure augmentation: Raising BP to supraphysiological levels to reverse ductal shunting doesn't reduce PVR and should be avoided 2
3. Ignoring LV dysfunction: The combination of PDA volume overload and septic cardiomyopathy can cause significant LV dysfunction—milrinone addresses both the PPHN and myocardial dysfunction 2
4. Premature weaning of pulmonary vasodilators: Rebound pulmonary hypertension can occur even without initial improvement; wean iNO to 1 ppm before discontinuation 2

Monitoring Strategy

• Serial echocardiography to assess:
  • Pulmonary artery pressures and shunt direction
  • LV and RV function
  • PDA size and flow characteristics
• Oxygenation index calculation: (mean airway pressure × FiO2 × 100) / PaO2 2
• Clinical signs of cardiac failure: hepatomegaly, pulmonary edema, increasing ventilator requirements

The hemodynamically significant PDA becomes your target only after the life-threatening conditions of septic shock and PPHN are controlled—attempting closure prematurely risks catastrophic decompensation.